ABOUT US SCIENCE PIPELINE PATIENTS & CAREGIVERS INVESTORS/MEDIA INSIDE SIGILON Developing potential functional cures for patients with chronic diseases Your browser doesn't support HTML5 video tag. A new treatment modality For many years, researchers have investigated cell and gene therapies as potential replacement therapies for severe chronic diseases. Despite major advancements in the field, these approaches carry a number of limitations including immune rejection, requirement for immune suppression, limited eligibility, durability and variability challenges, inability to re-dose and high manufacturing costs. To address these drawbacks, we developed our novel Shielded Living Therapeutics™ (SLTx) platform, which we believe has the potential to result in functional cures for patients with a wide range of chronic diseases. Leveraging the modularity of our SLTx platform, we have developed a growing pipeline of cell-based product candidates that have the potential to produce a wide range of missing or deficient therapeutic molecules (e.g. proteins, antibodies and enzymes). Moreover, our product candidates are designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression. We are presently focused on three therapeutic areas: rare blood disorders, lysosomal diseases, and endocrine and other chronic diseases. While the diseases we aim to treat are quite different, our products candidates themselves are generated through three common elements: the cell, the sphere, and our streamlined manufacturing process. The Shielded Living Therapeutics™ platform 1. Cell 2. Sphere 3. Manufacturing 1 Sigilon has developed proprietary engineered human cells that: Express high levels of desired protein(s) Deliver proteins at a constant rate or are programmed to “sense and respond” to the changing environment Survive well in an encapsulation environment Can be produced at large scale Are similar to cells previously used in clinical applications Provide the ability to easily insert new gene expression cassettes for different applications 2 3 In preclinical studies, components of our product candidates were well-tolerated with no notable adverse effects for up to 12 months. In addition, the spheres were successfully retrieved and redosed. Shielded Living Therapeutics™ products potentially capture benefits beyond existing therapies ©2021 Sigilon Therapeutics, Inc. The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners. Privacy Policy